arrow
C

Christoph Höeller

Medical University of Vienna
H指数:47
被引数:1.0万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years

原发性黑色素瘤假阴性诊断患者的生命损失年数。一项涉及9063例患者、为期28年的德国中央恶性黑色素瘤登记研究的回顾性研究

2026-07-020
OAAI
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention - Update 2026

欧洲共识性多学科指南:侵袭性皮肤鳞状细胞癌。第一部分:诊断与预防 - 2026年更新

2026-05-070
OAAI
Patient-reported outcomes with adjuvant nivolumab versus placebo after complete resection of stage IIB/C melanoma in the randomized phase 3 CheckMate 76 K trial

在随机III期CheckMate 76 K试验中,接受完全切除的IIB/C期黑色素瘤患者使用辅助纳武利尤单抗 versus 安慰剂治疗后的患者报告结局。

2025-05-010
OAAI
Management of Local Skin Reactions Caused by 5-FU 4% Cream for the Treatment of Actinic Keratosis: A Delphi Consensus

5-FU 4%乳膏治疗光线性角化症所致局部皮肤反应的管理:一项德尔菲共识

2025-04-300
OA
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncology

关于欧洲转移性黑色素瘤新型治疗方法可及性的最新进展——2024年欧洲黑色素瘤登记系统与欧洲皮肤肿瘤学会联合调查

2025-02-011
PRE
Adjuvant nivolumab v placebo in stage IIB/C melanoma: 3-year results from CheckMate 76K

辅助治疗中使用尼洛姆单抗与安慰剂对比治疗stage IIB/C黑色素瘤:CheckMate 76K研究3年结果

2024-09-014
PRE
Efficacy and safety of 'Second Adjuvant' therapy with BRAF/MEK inhibitors after local therapy for recurrent melanoma following adjuvant PD-1 based immunotherapy

基于辅助PD-1的免疫治疗后复发黑色素瘤局部治疗后使用BRAF/MEK抑制剂的 “第二佐剂” 治疗的疗效和安全性

2024-03-014
PRE
Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery
2024-02-231
OA
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (vol 29, pg 2835, 2023)
2024-01-040
OAAI
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial (16 OCT, 10.1038/s41591-023-02583-2, 2023 )

nivolumab在切除的IIB/C期黑色素瘤中的辅助治疗: 随机,3期CheckMate 76k试验的主要结果 (10.1038 10月16日/s41591-023-02583-2,2023)

2023-11-030
OAAI
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023
2023-11-0119
OA
European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023
2023-11-0123
OA
Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy
2023-10-205
PRE
Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

nivolumab在切除的IIB/C期黑色素瘤中的辅助治疗: 随机,3期CheckMate 76k试验的主要结果

2023-10-1653
OAAI
European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023
2023-10-0146
OAAI